{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T10:04:26Z","timestamp":1720173866628},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"crossref","award":["05-NV-001"],"award-info":[{"award-number":["05-NV-001"]}],"id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.neuropharm.2014.06.017","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T07:31:00Z","timestamp":1403681460000},"page":"548-553","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["P-glycoprotein activity in the blood\u2013brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment"],"prefix":"10.1016","volume":"85","author":[{"given":"Janine","family":"Doorduin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik F.J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudi A.","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neuropharm.2014.06.017_bib1","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.4049\/jimmunol.175.7.4189","article-title":"Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus","volume":"175","author":"Aravalli","year":"2005","journal-title":"J.\u00a0Immunol."},{"issue":"6","key":"10.1016\/j.neuropharm.2014.06.017_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11632020-000000000-00000","article-title":"Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?","volume":"26","author":"Attard","year":"2012","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/npp.1993.50","article-title":"Tissue concentrations of clozapine and its metabolites in the rat","volume":"9","author":"Baldessarini","year":"1993","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2014.06.017_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/mol.106.029512","article-title":"Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood\u2013brain barrier","volume":"71","author":"Bauer","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In\u00a0vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpsychires.2006.10.002","article-title":"Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients","volume":"42","author":"Bozina","year":"2008","journal-title":"J.\u00a0Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2014.06.017_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1590\/S1516-44462007000300004","article-title":"Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine","volume":"29","author":"Castro","year":"2007","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"4","key":"10.1016\/j.neuropharm.2014.06.017_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","article-title":"Evaluation of treatment-resistant schizophrenia","volume":"23","author":"Conley","year":"1997","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pscychresns.2010.05.002","article-title":"Regional increase in P-glycoprotein function in the blood\u2013brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function","volume":"183","author":"De Klerk","year":"2010","journal-title":"Psychiatry Res."},{"issue":"11","key":"10.1016\/j.neuropharm.2014.06.017_bib10","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2967\/jnumed.109.066647","article-title":"Neuroinflammation in schizophrenia-related psychosis: a PET study","volume":"50","author":"Doorduin","year":"2009","journal-title":"J.\u00a0Nucl. Med."},{"issue":"12","key":"10.1016\/j.neuropharm.2014.06.017_bib11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v69n1208","article-title":"Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study","volume":"69","author":"Dossenbach","year":"2008","journal-title":"J.\u00a0Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.neuropharm.2014.06.017_bib12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1017\/S1461145710000799","article-title":"Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients","volume":"13","author":"Drexhage","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2014.06.017_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1017\/S1461145710001653","article-title":"An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces","volume":"14","author":"Drexhage","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2014.06.017_bib14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds\u2013implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.06.017_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2014.06.017_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bjp.0705227","article-title":"Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in\u00a0vivo disposition of digoxin","volume":"139","author":"Goralski","year":"2003","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2014.06.017_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/mol.104.001503","article-title":"Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1","volume":"66","author":"Hartz","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/mol.105.017954","article-title":"Rapid modulation of P-glycoprotein-mediated transport at the blood\u2013brain barrier by tumor necrosis factor-alpha and lipopolysaccharide","volume":"69","author":"Hartz","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2014.06.017_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/dmd.31.3.319","article-title":"Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans","volume":"31","author":"Imbert","year":"2003","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib20","first-page":"625","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a Suggested solution based on in\u00a0vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2014.06.017_bib21","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","article-title":"Time course and biologic correlates of treatment response in first-episode schizophrenia","volume":"50","author":"Lieberman","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2014.06.017_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0969-8051(00)00137-2","article-title":"Graphical analysis of PET data applied to reversible and irreversible tracers","volume":"27","author":"Logan","year":"2000","journal-title":"Nucl. Med. Biol."},{"issue":"8","key":"10.1016\/j.neuropharm.2014.06.017_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"L\u00f6scher","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2014.06.017_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"issue":"6","key":"10.1016\/j.neuropharm.2014.06.017_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.tips.2010.03.003","article-title":"Regulation of P-glycoprotein and other ABC drug transporters at the blood\u2013brain barrier","volume":"31","author":"Miller","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.neuropharm.2014.06.017_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/10799900260100150","article-title":"Role of IFN-gamma and tumor necrosis factor-alpha in herpes simplex virus type 1 infection","volume":"22","author":"Minami","year":"2002","journal-title":"J.\u00a0Interferon Cytokine Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2014.06.017_bib27","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/17425255.4.10.1245","article-title":"A\u00a0critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain","volume":"4","author":"Roberts","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pbb.2012.04.002","article-title":"In\u00a0vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in\u00a0vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes","volume":"102","author":"Schmitt","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2014.06.017_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2014.06.017_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.ypg.0000194441.04684.db","article-title":"Association of treatment-resistant schizophrenia with the G2677A\/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene","volume":"16","author":"Takao","year":"2006","journal-title":"Psychiatr. Genet."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2014.06.017_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2014.06.017_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat","volume":"114","author":"Van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/j.neuropharm.2014.06.017_bib33","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","article-title":"Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study","volume":"64","author":"Van Berckel","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2014.06.017_bib34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neuropharm.2014.06.017_bib35","first-page":"1537","article-title":"Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging","volume":"46","author":"Wang","year":"2005","journal-title":"J.\u00a0Nucl. Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2014.06.017_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.neuropharm.2014.06.017_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0969-8043(02)00143-4","article-title":"An improved method for the preparation of [11C]verapamil","volume":"57","author":"Wegman","year":"2002","journal-title":"Appl. Radiat. Isot."},{"issue":"6","key":"10.1016\/j.neuropharm.2014.06.017_bib38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1159\/000110445","article-title":"TNF activates P-glycoprotein in cerebral microvascular endothelial cells","volume":"20","author":"Yu","year":"2007","journal-title":"Cell Physiol. Biochem."},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2014.06.017_bib39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1159\/000185558","article-title":"Neuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endothelia","volume":"22","author":"Yu","year":"2008","journal-title":"Cell Physiol. Biochem."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2014.06.017_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0014-2999(02)01661-8","article-title":"Effect of endotoxin on doxorubicin transport across blood\u2013brain barrier and P-glycoprotein function in mice","volume":"445","author":"Zhao","year":"2002","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2014.06.017_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.npp.1301181","article-title":"Risperidone and paliperidone inhibit p-glycoprotein activity in\u00a0vitro","volume":"32","author":"Zhu","year":"2007","journal-title":"Neuropsychopharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814002391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T15:16:29Z","timestamp":1689347789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814002391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":41,"alternative-id":["S0028390814002391"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.06.017","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P-glycoprotein activity in the blood\u2013brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}